Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Leah M. Marcotte, MD, Jeffrey Krimmel-Morrison, MD, and Joshua M. Liao, MD, MSc
Individuals can underperform in circumstances of shared accountability. In clinical settings, this is an unintended consequence of the health care sector’s complexity fragmentation.
AMA J Ethics. 2020;22(9):E802-807. doi:
10.1001/amajethics.2020.802.
Pamela B. Teaster, PhD, MA, MS and Al O. Giwa, LLB, MD, MBA, MBE
Since ageism contributes to global mental health inequity among older people, responding to their needs should be a clinical, ethical, and policy priority.
AMA J Ethics. 2023;25(10):E765-770. doi:
10.1001/amajethics.2023.765.
While useful in analyzing population trends in relative body weight, BMI possesses multiple shortcomings when used as an individualized health screening tool.
AMA J Ethics. 2023;25(7):E545-549. doi:
10.1001/amajethics.2023.545.
Lydia Smeltz, Susan M. Havercamp, PhD, and Lisa Meeks, PhD, MA
Lack of disability-competent health care contributes to inequitable health outcomes for persons with disabilities, the largest minoritized population in the world.
AMA J Ethics. 2024;26(1):E54-61. doi:
10.1001/amajethics.2024.54.